Mentions of brand or product names are for identification only and do not constitute endorsement.
You can find more information at Buffalopeptides.
Concussion protocols rarely include peptide nootropics. Standard care covers rest, graded return to activity, and sometimes stimulants or cholinesterase inhibitors. Semax and P21 sit outside that framework, though both have preclinical signals in traumatic brain injury models. This review compares the two in acute TBI contexts, with attention to intranasal delivery and whether they outperform conventional nootropics.
Scope of this review
Semax is a synthetic analogue of adrenocorticotropic hormone fragment 4-10. P21 is a small peptide derived from ciliary neurotrophic factor. Both have been studied in rodent TBI models. Human data are thinner. Semax has a longer clinical history in Russia and Eastern Europe for stroke and cognitive impairment. P21 remains largely preclinical. The question here is narrow: in the first days to weeks after concussion, do either of these peptides show stronger recovery signals than standard nootropics like piracetam or citicoline?
We make no representation about the suitability of any compound covered here for any particular purpose.
Study 1: Semax after experimental cortical contusion
A 2014 Russian study examined Semax in rats with controlled cortical impact. Animals received intranasal Semax daily for seven days after injury. Researchers measured Morris water maze performance and hippocampal BDNF expression. Treated rats showed faster escape latency improvements than saline controls. BDNF levels in the hippocampus increased by something like 30-50% relative to injured untreated animals.
Significance: the intranasal route mattered. Plasma half-life of Semax is short, but nasal delivery bypasses first-pass metabolism and allows peptide entry along olfactory and trigeminal pathways. The study did not compare Semax to piracetam. That limits direct claims about superiority over standard nootropics. Still, the BDNF increase is mechanistically relevant. Concussion often depresses BDNF signalling in the first week. Semax appears to blunt that drop.
Study 2: P21 and cognitive recovery after lateral fluid percussion
A 2019 study from the University of Kansas tested P21 in a lateral fluid percussion injury model. Rats received subcutaneous P21 for 14 days starting 24 hours post-injury. The design included a nootropic comparator group given donepezil. P21 improved novel object recognition and Barnes maze performance. Donepezil improved some measures but not spatial learning to the same degree.
Significance: P21 acts through TrkB receptor agonism and downstream Akt signalling. That is a different pathway from Semax, which primarily elevates BDNF and modulates enkephalin degradation. The 2019 trial suggested P21 effects were more durable after dosing stopped. One interpretation is that P21 promotes synaptic repair rather than temporary neurotransmitter support. That would matter in acute TBI, where the goal is lasting circuit restoration.
For a broader look at P21 in cognitive fog during medication titration, see P21 for Cognitive Fog During GLP-1 Dose Titration.
Study 3: Semax versus piracetam in mild TBI patients
A 2020 observational study from a Moscow neurology clinic followed 84 patients with mild traumatic brain injury. One group received intranasal Semax 0.1% for 10 days. Another received oral piracetam. Outcomes included the Montreal Cognitive Assessment and a symptom checklist at day 14 and day 30. Semax patients had faster MoCA gains at day 14. By day 30 the difference narrowed. Piracetam patients reported more residual headache and fatigue.
Significance: this is not a randomised trial. Selection bias is possible. But the early trajectory difference fits the animal data. Semax appears to accelerate early cognitive recovery, while piracetam has a flatter response. The study did not include P21. No head-to-head human data exist for Semax versus P21 in concussion.
Related mechanisms in GLP-1-induced cognitive slowing are discussed in P21 vs Semax for GLP-1-Induced Cognitive Slowing: BDNF vs NGF Pathways.
Study 4: P21 and neurogenesis after repetitive mild TBI
A 2022 preclinical study used a repetitive mild TBI model in mice. P21 was given intranasally every other day for three weeks. The researchers counted doublecortin-positive neurons in the dentate gyrus. P21 increased neurogenesis by roughly 40% over vehicle. It also reduced microglial activation in the hippocampus. A separate arm tested Dihexa, another peptide nootropic. Dihexa improved some measures but did not match P21 on neurogenesis.
Significance: repetitive mild TBI is closer to sports concussion than single severe impact. The neurogenesis effect is notable because hippocampal adult neurogenesis is sensitive to inflammatory cytokines after concussion. P21 appears to lower that inflammatory brake. Dihexa is a stronger synaptogenic agent but less selective for neurogenic niches. For post-concussion cognitive recovery, neurogenesis may matter more than synapse count in the first month.
For context on P21 in chemotherapy-related cognitive impairment, see P21 for Chemo Brain: Can This Nootropic Peptide Restore Cognitive Function After Cancer Treatment.
Study 5: Selank and MOTS-c as adjuncts in TBI protocols
Selank, a synthetic tuftsin analogue, has been studied for anxiety and cognitive impairment after brain injury. A 2018 Russian trial added Selank to standard rehabilitation in 60 patients with mild TBI. Anxiety scores dropped faster in the Selank group. Cognitive measures improved modestly. Selank does not directly target BDNF. It modulates GABAergic tone and immune peptides. That makes it a possible adjunct to Semax rather than a competitor.
MOTS-c is a mitochondrial-derived peptide. A 2023 mouse study tested MOTS-c after controlled cortical impact. It improved motor coordination and reduced oxidative stress markers in the cortex. MOTS-c has not been compared to Semax or P21 in TBI models. Its mechanism, AMPK activation and mitochondrial biogenesis, is orthogonal to neurotrophin signalling. In theory, combining a neurotrophin-targeting peptide with a mitochondrial peptide could address two injury cascades. No human data support that combination.
NAD+ precursors are sometimes grouped with peptide nootropics in concussion discussions. They raise cellular NAD+ and support sirtuin activity. They do not act through peptide receptors. Their role in acute TBI is being tested in small trials. They are not direct comparators to Semax or P21.
Synthesis
Semax and P21 both show preclinical efficacy in TBI models. Semax has more human data, mostly from Russian observational studies. P21 has stronger mechanistic evidence for neurogenesis and synaptic repair. Neither has been tested against the other in a randomised human trial. Standard nootropics like piracetam and citicoline have larger safety databases but weaker effect sizes in concussion-specific cognitive outcomes.
The intranasal route is a key variable. Semax is well characterised for nasal delivery. P21 has been given subcutaneously in most studies, with fewer intranasal pharmacokinetic data. If intranasal P21 reaches brain parenchyma at effective concentrations, it could match Semax on convenience. That remains unproven.
One open question is timing. Animal studies start treatment within 24 hours. Human concussion patients often present days later. The therapeutic window for neurotrophin-based repair may close within the first week. A 2021 review of peptide nootropics in TBI noted that most positive preclinical results come from early intervention. Delayed treatment shows smaller effects. That pattern holds for Semax and P21.
Another open question is combination therapy. Semax plus P21 would target BDNF and TrkB simultaneously. That could be redundant or synergistic. No published study has tested the combination in TBI. Selank could be added for anxiety and sleep disruption, which are common after concussion. MOTS-c could address mitochondrial dysfunction. These are speculative stacks, not evidence-based protocols.
For a discussion of Semax and P21 as prophylactic nootropics before cognitive testing, see Semax and P21 as Prophylactic Nootropics Before High-Stakes Cognitive Testing.
Open questions
First, does intranasal P21 achieve brain concentrations comparable to subcutaneous dosing? Pharmacokinetic studies are missing. Second, what is the optimal treatment window after concussion? Animal data suggest early intervention, but human concussion care is often delayed. Third, do Semax and P21 outperform citicoline or piracetam in a randomised design? No such trial exists. Fourth, are the neurogenic effects of P21 durable beyond the treatment period? The 2019 Kansas study suggested persistence, but longer follow-up is needed. Fifth, can peptide nootropics be safely combined with standard concussion rehabilitation? Interaction data are absent.
Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input.